Furthermore, there is a dearth of genomic data in SCLC, primarily characterized by TP53 and RB1 alterations [28], which suggests that biomarkers should be pursued in areas of plentiful data such as CT scans, tissue immunohistochemical slides, and cell lines to determine how the self-similar and fractal nature of these images can act as a predictive model for clinical management. Here, RB1 is linked to small cell lung carcinoma.